Caris Life Sciences launched Caris Detect™, an AI-powered platform using whole-genome and transcriptome analysis trained on over 50 billion molecular markers from over 1 million patient cases to detect cancer signals in blood.
Published
Signal category
Products & Services
Quote
“Caris Detect™ uses whole-genome and transcriptome analysis and is AI trained on more than 50 billion molecular markers from over 1 million patient cases to identify patterns associated with cancer signals in blood.”
— Caris Life Sciences team
Company
Caris Life Sciences
Fulfilling the promise of precision medicine through quality and innovation.
- Industry
- Biotechnology Research
- Location
- Irving, US
- Company size
- 1,721 employees
Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.
Founded 1996